Drug Information

Drug General Information
Drug ID
D05DXZ
Former ID
DIB004238
Drug Name
RXI-109
Synonyms
Self-delivering rxRNA (sd-rxRNA) therapy (antiscarring), RXi Pharmaceuticals
Drug Type
Antibody
Indication Fibrosis [ICD9: 709.2; ICD10:L90.5] Phase 2 [524924]
Company
Rxi pharmaceuticals
Target and Pathway
Target(s) Connective tissue growth factor Target Info [544379]
KEGG Pathway Hippo signaling pathway
NetPath Pathway TGF_beta_Receptor Signaling Pathway
Pathway Interaction Database amb2 Integrin signaling
TGF-beta receptor signaling
Reactome PPARA activates gene expression
YAP1- and WWTR1 (TAZ)-stimulated gene expression
WikiPathways Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
Hair Follicle Development: Induction (Part 1 of 3)
Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)
YAP1- and WWTR1 (TAZ)-stimulated gene expression
References
Ref 524924ClinicalTrials.gov (NCT02246465) A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars. U.S. National Institutes of Health.
Ref 544379Cyr61/CTGF/Nov family proteins in gastric carcinogenesis. World J Gastroenterol. 2014 February 21; 20(7): 1694-1700.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.